JINLING PHARM.(SZ:000919)2023-03-23 16:00Financial Performance - The company's operating revenue for 2022 was approximately ¥2.67 billion, a decrease of 4.91% compared to ¥2.81 billion in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥105.28 million, down 12.72% from ¥120.63 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥63.72 million, a decline of 11.70% from ¥72.16 million in 2021[24]. - The cash flow from operating activities for 2022 was approximately ¥260.59 million, a decrease of 10.76% compared to ¥292.03 million in 2021[24]. - The total assets at the end of 2022 were approximately ¥4.54 billion, an increase of 2.15% from ¥4.45 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥2.99 billion, up 2.27% from ¥2.93 billion at the end of 2021[24]. - The basic earnings per share for 2022 were ¥0.2089, down 12.70% from ¥0.2393 in 2021[24]. - The weighted average return on equity for 2022 was 3.54%, a decrease of 0.62% from 4.16% in 2021[24]. - The company achieved total operating revenue of 2,670.968 million yuan and a net profit attributable to shareholders of 1,052.819 million yuan in 2022[48]. - The company reported a gross margin of 34.37% for pharmaceutical production and sales, which is an increase of 1.47% compared to the previous year[59]. - The company reported a total revenue of 1,273,108,500 CNY for its subsidiary Suqian Hospital, with a net profit of 32,964,877 CNY[88]. - The company reported a total revenue of 2.8836 billion CNY for the year 2022, reflecting a significant growth compared to the previous year[106]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 10%[114]. Dividend Distribution - The company plans to distribute a cash dividend of 1.0 RMB per 10 shares (including tax) based on a total of 511,136,000 shares[3]. - The cash dividend distribution plan for the reporting period included a cash dividend of 1.0 yuan per 10 shares, totaling 51,113,600 yuan, which represents 100% of the total profit distribution[138]. - The company has maintained a complete decision-making process for its cash dividend policy, ensuring the protection of minority shareholders' rights[138]. - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares, totaling CNY 51,113,600.00, with the remaining undistributed profit of CNY 811,804,540.03 carried forward to future years[140]. Business Operations and Strategy - The company has expanded its business scope to include medical services and health care services following acquisitions in 2003 and 2018[22]. - The company’s business model remains unchanged compared to the previous year, focusing on pharmaceutical manufacturing and healthcare services[44]. - The company is focusing on expanding its market presence through diversified product sales, including medical devices and agricultural products[49]. - The company is committed to enhancing its operational efficiency by dynamically adjusting production plans and improving resource allocation[49]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development and strategic acquisitions[110]. - The company is strategically positioned to leverage its experienced management team to drive future growth and operational efficiency[110]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers in 2023[114]. Research and Development - The company invested CNY 74.17 million in R&D during the reporting period, representing a year-on-year increase of 30%[52]. - Research and development expenses increased by 30.09% to CNY 74,170,064.98, driven by new projects[67][68]. - The company has a total of 13 employees with doctoral degrees and 388 with master's degrees, reflecting a strong educational background among its workforce[134]. - The company has established a dedicated committee for innovation development, aiming to enhance its competitive edge in the market[112]. - The company’s new product "Cicada Slough Cough Granules" has completed clinical research and is awaiting approval[54]. - The company has been actively involved in various technology projects, including the successful application for the Jiangsu Province Science and Technology Achievement Transformation Project[52]. Market and Competition - The company acknowledges risks related to industry policy changes, market competition, and raw material price fluctuations[3]. - The company aims to enhance its product quality and R&D capabilities to maintain competitive advantages in a highly concentrated market[91]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[114]. Governance and Compliance - The company has implemented a governance structure that complies with relevant laws and regulations, enhancing its governance level[96]. - The board of directors operates independently, with specialized committees focusing on strategy, audit, nomination, and remuneration[97]. - The company emphasizes transparent information disclosure, utilizing multiple media outlets to ensure all investors have equal access to information[98]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring compliance with tax regulations[100]. - The company has implemented a comprehensive internal control system to ensure compliance with relevant laws and regulations[148]. - The internal control audit report issued on March 24, 2023, received a standard unqualified opinion, confirming the effectiveness of financial reporting controls[153]. Environmental Management - The company has implemented self-monitoring plans in accordance with relevant regulations, ensuring stable compliance with pollutant discharge[164]. - The company invested CNY 9.2799 million in environmental protection efforts[168]. - The company maintained compliance with environmental regulations, adhering to standards set by various environmental protection laws[156]. - Jinling Pharmaceutical's environmental management practices include strict adherence to wastewater and air quality standards, demonstrating commitment to sustainability[156]. Employee Management - The total number of employees at the end of the reporting period was 4,880, with 3,475 in technical roles, 458 in production, and 95 in sales[134]. - The company conducted 481 training programs in 2022, achieving an overall training plan completion rate of over 85% and spending over 3 million yuan on education expenses[136]. - The company has implemented a flexible benefits plan to meet diverse employee welfare needs and enhance employee satisfaction[135]. - The company has established a dual-driven talent development system focusing on theoretical learning and practical training[135]. Legal and Regulatory Matters - The company has not reported any significant changes in its business, products, or services during the reporting period[66]. - There were no significant lawsuits or arbitration matters during the reporting period[188]. - The company reported no violations of external guarantees during the reporting period[181]. - The company did not experience any bankruptcy reorganization during the reporting period[187].